An Award Code applied to grants in IMPACII to characterize the percentage of research dollars applied to Basic, Applied, and Development (B/A/D) research. The sum of Basic + Applied + Develpmental percentages must sum to equal 100.

Broad Agency Announcement (BAA) - in addition to the definition found in FAR §2.101, a BAA is a method used by the NIH to solicit proposals for research and development projects. Under a BAA, the NIH may award a contract and any instrument it is authorized to use including but not limited to a grant, cooperative agreement or other transaction. The NIH shall only award the type(s) of instrument(s) stated in the announcement.

For NIH policy and guidance regarding Broad Agency Announcements (BAA), see NIH Policy Manual 6035.

This term has been replaced by "Final Proposal Revision".

The National Institute of Environmnetal Health Science (NIEHS) and the National Cancer Institute (NCI) co-fund the Breast Cancer and the Environment Research Program (BCERP), which supports the enhancement of our knowledge regarding environmental and genetic factors underlying breast cancer risk over women's lifespans. Through the integration of experimental models and human studies, the BCERP Transdisciplinary Research Projects are studying how environmental exposures during specific times (windows of susceptibility), such as puberty or during pregnancy, may increase breast cancer risk. The BCERP Coordinating Center serves as a hub for communication about priority research topics and scientific findings from the program that can inform prevention.

The BCERP is the next phase of a program that began with the Breast Cancer and the Environment Research Centers (BCERC) in 2003.

Also see the NCI DCCPS Epidemiology and Genomics Research Program's Breast Cancer and the Environment Research Program webpage and the BCERP.org webpage.

A NCI-sponsored collaborative network of mammography registries with linkages to tumor registries and pathology data. The Breast Cancer Surveillance Consortium (BCSC) was established in 1994 in response to a legislative mandate from the 1992 Mammography Quality Standards Act (MQSA)to evaluate the performance of mammography in community practice and related screening and breast cancer outcomes. Several SEER investigators participate in the Consortium.

After many years of service to the NIH Bioengineering community, the NIH Bioengineering Consortium (BECON) has completed its mission. Bioengineering has now become an important activity supported at nearly every NIH institute and center, and much of what BECON had done has now been well integrated across the NIH.

Many of the bioengineering funding announcements and technical reports at the BECON website have migrated to the National Institute of Biomedical Imaging and Bioengineering

In particular,

• NIH Bioengineering Research Funding Announcements and Information
• NIH Nanotechnology Research and Information
• For other BECON-related information, please contact the National Institute of Biomedical Imaging and Bioengineering.

A consortium of representatives from each of the NIH institutes and centers that serves as the focus of biomedical computing issues at the NIH. The mission of the Biomedical Information Science and Technology Initiative (BISTI) is to make optimal use of computer science and technology to address problems in biology and medicine by fostering new basic understandings, collaborations, and transdisciplinary initiatives between the computational and biomedical sciences.

The Biologics License Application (BLA) is a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce (21 CFR §601.2).

Visit the FDA's Biologics License Applications (BLA) Process (CBER) webpage for additional information.

Biological Materials Licenses grant to the licensee the right to make, use and sell commercially useful biological materials that are not in the public domain and for which patent protection cannot or will not be obtained. This type of license typically is nonexclusive and facilitates the commercial development of biological materials developed in NIH laboratories.

Visit the NCI Technology Transfer Center website for further information.

The Blood and Marrow Clinical Trials Network (BMT CTN) is supported by a U10 grant from the NHLBI and NCI, with the NHLBI as the lead institute. This network is managed jointly among NHLBI and NCI/CTEP program officers. The BMT CTN was established in October of 2001 to conduct large, multi-institutional clinical trials addressing important issues in hematopoietic stem cell transplantation (HCT). The participating BMT CTN investigators collaborate to implement and complete well-designed clinical trials of high scientific merit, offering trial participation to patients in all regions of the United States.

An eRA Commons Account Role, the Business Official (BO) role is used with xTrain; which is a service to electronically manage appointments for awarded Training Grants.

NIH Information Technology Board of Governors, which advises NIH on the overhaul of its major enterprise systems. A steering committee with strong community representation provides liaison between BOG and other groups, including the ERA Project Team, Extramural Program Management Committee, and the NIH Office of Extramural Research.

1. A blanket purchase agreement (BPA) is a simplified method of filling anticipated repetitive needs for supplies or services by establishing "charge accounts" with qualified sources of supply (see FAR subpart 16.7 for additional coverage of agreements).
2. BPAs should be established for use by an organization responsible for providing supplies for its own operations or for other offices, installations, projects, or functions. Such organizations, for example, may be organized supply points, separate independent or detached field parties, or one-person posts or activities.
3. The use of BPAs does not exempt an agency from the responsibility for keeping obligations and expenditures within available funds.

Quoted from §13.303-1 of the Federal Acquisition Regulation.

The annual inflationary index for the cost of conducting biomedical research. The BRDPI was developed for the NIH to measure real annual changes in the prices of items and services required for research and development (R&D) activities.

For additional information, visit the NIH Office of Budget's Price Indexes webpage.

The cite>Biomedical Research Integrated Domain Group (BRIDG) Model is a collaborative effort engaging stakeholders from the Clinical Data Interchange Standards Consortium (CDISC), the HL7 BRIDG Work Group, the International Organization for Standardization (ISO), the US National Cancer Institute (NCI), and the US Food and Drug Administration (FDA). The goal of the BRIDG Model is to produce a shared view of the dynamic and static semantics for the domain of basic, pre-clinical, clinical, and translational research and its associated regulatory artifacts. This domain of interest is further defined as:

• The data, organization, resources, rules, and processes involved in the formal assessment of the utility, impact, or other pharmacological, physiological, or psychological effects of a drug, procedure, process, subject characteristic, biologic, cosmetic, food or device on a human, animal, or other subject or substance plus all associated regulatory artifacts required for or derived from this effort, including data specifically associated with postmarket surveillance and adverse event reporting.

Advises the Director and Deputy Director, NCI, and the Director of each NCI Division on a wide variety of matters concerning scientific program policy, and progress and future of direction of extramural research programs and makes recommendation on research priorities conducted or supported by the NCI, This includes the evaluation of NCI awarded grants, cooperative agreements and contracts and concept review of those activities which it considers meritorious and consistent with the NCI's programs. the advisory role of the Board is scientific and doesn't include deliberation on matters of policy.

For additional information, visit the NCI DEA BSA webpage.

The Board shall advise the Director of CCR, and the Director and Deputy Director, NCI, on a wide variety of matters concerning scientific program policy and progress and future direction of research programs in the areas of basic sciences including experimental immunology, immunobiology, tumor immunology and biology, biochemistry, molecular immunoregulation, cellular oncology, cell biology, genetics, molecular biology, tumor cell biology, tumor virus biology, experimental pathology, molecular oncology, molecular virology, cellular and molecular biology, human carcinogenesis, viral carcinogenesis, biology, chemoprevention, carcinogenesis and tumor promotion, experimental carcinogenesis, basic carcinogenesis, biological chemistry, experimental immunology, biochemical physiology, medicinal chemistry, nutritional and molecular regulation, immune cell biology, leukocyte biology, molecular pharmacology, and mathematical biology. The members of this board are appointed to 4-year terms by the NCI Director.

For additional information, visit the NCI DEA Board of Scientific Counselors - Basic Sciences webpage.

The Board shall advise the Directors of CCR and DCEG, and the Director and Deputy Director, NCI, on a wide variety of matter s concerning scientific program policy and progress and future direction of research programs in the areas of dermatology, metabolism, surgery, pathology, pediatrics, clinical pharmacology, clinical research, oncology, radiation oncology, radiation biology, biomarkers and prevention research.

For additional information, visit the NCI DEA Board of Scientific Counselors - Clinical Sciences and Epidemiology webpage.